-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Pharvaris (NASDAQ:PHVS) Posts Earnings Results, Beats Expectations By $0.19 EPS
Pharvaris (NASDAQ:PHVS) Posts Earnings Results, Beats Expectations By $0.19 EPS
Pharvaris (NASDAQ:PHVS – Get Rating) posted its quarterly earnings results on Monday. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.19, MarketWatch Earnings reports.
Pharvaris Trading Down 2.6 %
NASDAQ PHVS opened at $9.07 on Wednesday. The company has a 50-day moving average price of $17.03 and a two-hundred day moving average price of $18.05. Pharvaris has a 52 week low of $8.55 and a 52 week high of $27.50. The stock has a market cap of $288.79 million, a price-to-earnings ratio of -3.49 and a beta of -0.19.
Get Pharvaris alerts:Institutional Investors Weigh In On Pharvaris
A hedge fund recently raised its stake in Pharvaris stock. Bank of America Corp DE boosted its holdings in Pharvaris (NASDAQ:PHVS – Get Rating) by 1,054.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,772 shares of the company's stock after acquiring an additional 5,272 shares during the quarter. Bank of America Corp DE's holdings in Pharvaris were worth $105,000 at the end of the most recent quarter. 70.21% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of analysts have weighed in on PHVS shares. Bank of America cut shares of Pharvaris from a "neutral" rating to an "underperform" rating and dropped their target price for the stock from $26.00 to $13.00 in a report on Monday, August 22nd. SVB Leerink cut their target price on shares of Pharvaris from $25.00 to $20.00 and set an "outperform" rating on the stock in a report on Wednesday. Oppenheimer decreased their target price on Pharvaris from $48.00 to $22.00 and set an "outperform" rating for the company in a research note on Tuesday, August 23rd. Morgan Stanley cut Pharvaris from an "overweight" rating to an "equal weight" rating and dropped their price target for the stock from $40.00 to $10.00 in a research report on Tuesday, August 23rd. Finally, JMP Securities reduced their price objective on Pharvaris from $34.00 to $18.00 and set a "mkt outperform" rating for the company in a research report on Tuesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, Pharvaris has an average rating of "Hold" and a consensus target price of $16.60.Pharvaris Company Profile
(Get Rating)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).
Recommended Stories
- Get a free copy of the StockNews.com research report on Pharvaris (PHVS)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
Pharvaris (NASDAQ:PHVS – Get Rating) posted its quarterly earnings results on Monday. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.19, MarketWatch Earnings reports.
纳斯达克(股票代码：PHVS-GET Rating)周一公布了季度收益报告。MarketWatch收益报告显示，该公司本季度每股收益(EPS)为0.38美元，比市场普遍预期的每股收益(0.57美元)高出0.19美元。
Pharvaris Trading Down 2.6 %
Pharvaris股价下跌2.6%
NASDAQ PHVS opened at $9.07 on Wednesday. The company has a 50-day moving average price of $17.03 and a two-hundred day moving average price of $18.05. Pharvaris has a 52 week low of $8.55 and a 52 week high of $27.50. The stock has a market cap of $288.79 million, a price-to-earnings ratio of -3.49 and a beta of -0.19.
纳斯达克PHV周三开盘报9.07美元。该公司的50日移动均线价格为17.03美元，200日移动均线价格为18.05美元。Pharvaris的52周低点为8.55美元，52周高点为27.50美元。该股市值为2.8879亿美元，市盈率为-3.49倍，贝塔系数为-0.19。
Institutional Investors Weigh In On Pharvaris
机构投资者看好Pharvaris
A hedge fund recently raised its stake in Pharvaris stock. Bank of America Corp DE boosted its holdings in Pharvaris (NASDAQ:PHVS – Get Rating) by 1,054.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,772 shares of the company's stock after acquiring an additional 5,272 shares during the quarter. Bank of America Corp DE's holdings in Pharvaris were worth $105,000 at the end of the most recent quarter. 70.21% of the stock is currently owned by institutional investors and hedge funds.
一家对冲基金最近增持了Pharvaris股票。根据美国银行在最近提交给美国证券交易委员会(美国证券交易委员会)的文件中，该公司在第一季度将其在Pharvaris(纳斯达克：PHV-GET评级)的持股增加了1,054.4%。该公司在本季度额外收购了5272股后，拥有5772股该公司的股票。截至最近一个季度末，美国银行(Bank Of America Corp DE)持有的Pharvaris股份价值10.5万美元。70.21%的股票目前由机构投资者和对冲基金持有。
Analyst Ratings Changes
分析师评级发生变化
Pharvaris Company Profile
Pharvaris公司简介
(Get Rating)
(获取评级)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).
Pharvaris N.V.是一家临床阶段的生物制药公司，专注于罕见疾病疗法的开发和商业化。该公司开发了PHA121，这是一种小分子缓激肽B2受体拮抗剂，目前处于第二阶段临床试验，用于治疗遗传性血管性水肿(HAE)。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Pharvaris (PHVS)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 免费获取StockNews.com关于Pharvaris(PHV)的研究报告
- 这三份报告将告诉我们许多关于当前经济的情况。
- 下面的五个是不是打得太高了？
- 这就是现在对标准普尔500指数的预期
- 关于甲骨文的FQ1报告，你需要知道的两件事
- 波动市场的三只价值股
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
接受Pharvaris Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Pharvaris和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧